Long-Acting Injectable Antipsychotics Slash Rehospitalization in Schizophrenia

For decades, psychiatrists have debated whether newer is truly better when it comes to antipsychotic medication. A new real-world study from Italy suggests that, at least for long-acting injectable treatments in schizophrenia, the answer may be surprisingly neutral: both first- and second-generation long-acting injectable antipsychotics dramatically reduced rehospitalizations, relapses, and suicide attempts, with no meaningful difference between the two generations. The findings, published in BMC Psychiatry, offer a rare mirror-image comparison drawn directly from clinical practice rather than the artificial conditions of a randomized trial.

The research team, led by Renato de Filippis and Pasquale De Fazio at the University Magna Graecia of Catanzaro, set out to address a persistent uncertainty in schizophrenia care. Long-acting injectable antipsychotics, or LAIs, deliver medication steadily over weeks or months, bypassing the daily pill-taking that often falters in chronic illness. While LAIs are widely accepted as effective, the choice between older first-generation formulations and newer second-generation ones has remained unclear, with guidelines offering limited real-world evidence to guide clinicians.

To capture the true impact of switching to an injectable, the investigators used a mirror-image design, comparing each patient’s own clinical course before and after LAI initiation. They followed 133 patients with schizophrenia spectrum disorders for three years retrospectively and three years prospectively, tracking hospital admissions, days spent in hospital, clinical relapses, and suicide attempts. This approach controls implicitly for each individual’s baseline severity, since every patient serves as their own comparison.

The sample was predominantly male, about 69 percent, with a mean age of 50.3 years. Most patients were single, Caucasian, and carried a long history of illness, averaging 20.1 years since diagnosis and 17.1 years of antipsychotic treatment. These were not newly diagnosed individuals responding to a first intervention; they were patients with entrenched, difficult-to-treat conditions, which makes the scale of improvement all the more striking.

After switching from oral antipsychotics to LAI formulations, the proportion of patients requiring hospital admission plummeted from 53.4 percent to just 6.0 percent over the three-year observation window. The average duration of hospitalization collapsed from 14.26 days to 1.35 days, a reduction of roughly 90 percent. The researchers emphasize that this benefit appeared consistently across all patient subgroups and treatment conditions, suggesting the effect was not driven by a particular drug, dose, or demographic profile.

Clinical relapses and suicide attempts also fell significantly after LAI initiation. Relapses, which often precipitate hospitalization and mark a deterioration in the course of illness, declined in parallel with admission rates. Suicide attempts, a devastating and unfortunately common outcome in schizophrenia, decreased as well, hinting that stable medication delivery may protect against acute crises beyond its effect on psychotic symptoms alone.

Crucially, when the researchers compared patients receiving first-generation LAIs with those on second-generation LAIs, they found no statistically significant differences in improvement between the two groups. Both generations produced comparable reductions in hospitalization days, relapses, and suicide attempts over the three-year follow-up. The incidence of suicide attempts did not differ between the cohorts, and neither did the prevention of relapse.

This equivalence carries real weight for treatment decisions. Second-generation antipsychotics were introduced partly to reduce the movement-related side effects, such as tremor and rigidity, associated with older drugs, and they have often been presumed clinically superior. The new data suggest that, in real-world practice, efficacy may not be the deciding factor between generations. Instead, the authors argue, treatment choice should be guided by tolerability, side-effect profiles, patient preferences, and clinician judgment rather than assumed differences in effectiveness.

The study’s design has limits that the authors are careful to acknowledge. Because it is observational and uses a mirror-image comparison rather than randomization, residual confounding remains possible. Patients who switch to LAIs may differ systematically from those who do not, and the natural course of illness can change over time independent of treatment. The findings should therefore not be read as definitive proof of comparative effectiveness between first- and second-generation LAIs, but rather as strong real-world evidence that LAI treatment itself is associated with sustained medium- to long-term reductions in rehospitalization and relapse.

Nevertheless, the magnitude of the results is hard to dismiss. A drop from more than half of patients hospitalized to just 6 percent, sustained over three years in a chronic, treatment-refractory population, represents a substantial gain in both human welfare and health system burden. As mental health services worldwide grapple with revolving-door admissions and rising costs, the study adds momentum to the argument that long-acting injectable strategies deserve earlier consideration, and that the oldest and newest tools in the injectable arsenal may be more alike than different.

The mirror-image approach used in this study deserves closer attention, because it is one of the most practical ways to evaluate long-term psychiatric treatments when randomized trials are difficult to run. By comparing each patient with themselves across a fixed boundary in time, the design partially neutralizes the stable personal factors, such as illness severity, personality, and social circumstances, that normally confound between-group comparisons. In schizophrenia research, where relapse rates and hospital use vary enormously between individuals, this within-person logic is particularly valuable. It cannot, however, account for changes that unfold over time independently of treatment, such as shifts in family support, housing, or the natural waxing and waning of the illness itself, which is why the authors remain cautious about causal claims.

The choice of outcomes also reflects what matters most to patients and health systems alike. Hospital admissions are among the most disruptive events in the life of a person with schizophrenia, often marking loss of employment, housing instability, and strained family relationships, while also representing a large share of the direct costs of treating psychotic disorders. Days spent in hospital serve as a proxy for episode severity, not merely frequency, so the roughly ninety percent reduction in average hospitalization duration suggests that LAI treatment did not simply prevent marginal admissions but may have blunted the intensity of the crises that did occur. The parallel decline in suicide attempts is especially noteworthy, since suicidal behavior in schizophrenia spectrum disorders is a leading cause of premature mortality, and few pharmacological interventions have demonstrated measurable effects on this outcome in routine care.

The demographic profile of the cohort also shapes how the findings should be generalized. The predominance of middle-aged men with two decades of illness and prior antipsychotic exposure means the results speak most directly to chronic, established disease rather than first-episode psychosis, where treatment trajectories and side-effect sensitivities can differ considerably. Younger patients, women, and those newly diagnosed may respond differently to injectable strategies, and the balance of tolerability concerns between the two antipsychotic generations can shift with age and comorbid metabolic or cardiovascular conditions. The authors note that the benefit appeared consistently across subgroups within this cohort, but the cohort itself defines the boundaries of reasonable extrapolation.

It is also worth situating the equivalence finding within the broader history of antipsychotic pharmacology. First-generation drugs act primarily as potent dopamine receptor blockers and are associated with a higher burden of extrapyramidal motor side effects, while second-generation agents engage a broader range of receptor systems and were developed partly to improve tolerability and possibly negative symptoms. Decades of comparative research have generally shown modest or inconsistent advantages for the newer class on efficacy outcomes, so the present result, in which both LAI generations produced similar reductions in hospitalization, relapse, and suicidal behavior, aligns with that larger body of evidence rather than overturning it. What the study adds is a real-world, head-to-head comparison of the injectable formulations specifically, a setting where adherence is no longer the dominant variable separating oral treatments.

From a health services perspective, the implications are considerable. Rehospitalization, sometimes described as the revolving-door phenomenon, consumes a disproportionate share of mental health budgets and is a frequent target of quality improvement programs. If a substantial fraction of admissions in chronic schizophrenia can be avoided through sustained injectable treatment, the economic argument for expanding LAI use becomes easier to make, independent of questions about which generation to prefer. The finding that choice between generations can rest on tolerability, patient preference, and individual clinical circumstances is, in practice, an argument for shared decision-making: patients who are offered a formulation aligned with their side-effect concerns and lifestyle may be more likely to accept and continue it, which is itself a precondition for the outcomes observed here.

Finally, the study’s open-access publication and its documentation through a STROBE checklist reflect growing expectations for transparency in observational research. The supplementary analyses, including multivariate tests of time and time-by-treatment effects, allow readers to examine how the pre-post differences were modeled and how robust the within-group improvements were across the two treatment arms. As with all mirror-image evidence, the natural next step would be randomized or propensity-matched comparisons to confirm the equivalence suggested here, but for clinicians weighing an LAI recommendation today, the practical message is clear: the injectable route itself, whether built on an older or a newer molecule, appears associated with durable reductions in the crises that define much of the burden of schizophrenia.

Subject of Research: Reducing re-hospitalization in schizophrenia: real-world comparison of first- vs. second-generation long-acting injectable antipsychotics

Article Title: Reducing re-hospitalization in schizophrenia: real-world comparison of first- vs. second-generation long-acting injectable antipsychotics

Article References: de Filippis, R., Aloi, M., Pilieci, A. M., Carbone, E. A., Rania, M., D’Onofrio, E., Procopio, C., Segura-Garcia, C., & De Fazio, P. (2026). Reducing re-hospitalization in schizophrenia: real-world comparison of first- vs. second-generation long-acting injectable antipsychotics. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08550-8

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08550-8

Keywords: Reducing, re-hospitalization, schizophrenia, real-world, comparison, first-, second-generation, long-acting, injectable, antipsychotics, scientific research